Flupentixol Suppliers & Bulk Manufacturers
Available Forms: Intramuscular injection
Available Strengths: 20 mg/mL, 40 mg/mL
Reference Brands: Fluanxol, Depixol(EU)
Category:
Antipsychotropic Drugs
Flupentixol, marketed as Fluanxol and Depixol, is used in Europe to manage schizophrenia and depression. Available in tablets and depot injections, it’s not approved in the US but widely used in the EU. Pharma B2B platforms source Flupentixol for mental health therapies and international neuropsychiatric supply chains.
Flupentixol is available in Intramuscular injection
and strengths such as 20 mg/mL, 40 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Flupentixol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Flupentixol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Flupentixol is a typical antipsychotic drug commonly used in Europe to treat schizophrenia and depressive disorders. It is available in oral tablet form (0.5 mg, 1 mg, and 3 mg) and as a long-acting intramuscular injection (Flupentixol decanoate 20 mg/mL and 40 mg/mL). Marketed under brand names such as Fluanxol and Depixol, it is widely prescribed in EU countries, including the UK, Germany, and Scandinavia. Although not approved in the US, Flupentixol remains a critical neuroleptic in the global pharma supply chain. It is in demand among B2B pharmaceutical distributors for mental health and psychiatric care therapies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing